AU2001281396A1 - Novel compositions and methods for treatment of male erectile dysfunction - Google Patents

Novel compositions and methods for treatment of male erectile dysfunction

Info

Publication number
AU2001281396A1
AU2001281396A1 AU2001281396A AU8139601A AU2001281396A1 AU 2001281396 A1 AU2001281396 A1 AU 2001281396A1 AU 2001281396 A AU2001281396 A AU 2001281396A AU 8139601 A AU8139601 A AU 8139601A AU 2001281396 A1 AU2001281396 A1 AU 2001281396A1
Authority
AU
Australia
Prior art keywords
treatment
methods
erectile dysfunction
novel compositions
male erectile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001281396A
Other languages
English (en)
Inventor
Irwin Goldstein
Noel Kim
Iain Mccauley
Abdul Traish
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston University
Original Assignee
Boston University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston University filed Critical Boston University
Publication of AU2001281396A1 publication Critical patent/AU2001281396A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001281396A 2000-08-08 2001-08-08 Novel compositions and methods for treatment of male erectile dysfunction Abandoned AU2001281396A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22386500P 2000-08-08 2000-08-08
US60223865 2000-08-08
PCT/US2001/041638 WO2002011729A1 (fr) 2000-08-08 2001-08-08 Compositions et methodes de traitement de la dyserection masculine

Publications (1)

Publication Number Publication Date
AU2001281396A1 true AU2001281396A1 (en) 2002-02-18

Family

ID=22838272

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001281396A Abandoned AU2001281396A1 (en) 2000-08-08 2001-08-08 Novel compositions and methods for treatment of male erectile dysfunction

Country Status (2)

Country Link
AU (1) AU2001281396A1 (fr)
WO (1) WO2002011729A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003257289A1 (en) * 2002-07-26 2004-02-16 Kenneth W. Adams Pharmaceutical compositions for penis enlargement
GB201221032D0 (en) * 2012-11-22 2013-01-09 Mens Health Ltd Method of treatment
WO2018220232A1 (fr) * 2017-06-02 2018-12-06 Universite De Versailles-St Quentin En Yvelines Produit d'association pharmaceutique comprenant une toxine botulinique pour le traitement d'un dysfonctionnement érectile

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction

Also Published As

Publication number Publication date
WO2002011729A1 (fr) 2002-02-14

Similar Documents

Publication Publication Date Title
HUP0204159A3 (en) Prostaglandin compositions and their use for preparation of pharmaceutical compositions for treatment male erectile dysfunction
IL153492A0 (en) Treatment of male sexual dysfunction
AU2001250821A1 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
AU2002230423A1 (en) Serotonergic compositions and methods for treatment of mild cognitive impairment
HUP0401816A3 (en) Prostaglandin compositions and their use for preparation of medicaments sutable for treatment of male erectile dysfunction
AU9092501A (en) Compositions and methods for inhibition of hiv-1 infection
EP1252325A4 (fr) Compositions et methodes permettant d'inhiber une infection a vih-1
HUP0301892A3 (en) Pharmaceutical compositions for treatment of sexual dysfunction and their preparation
AU2002352533A1 (en) Methods and compositions for treatment of gastric diseases
AU2001281140A1 (en) Anti-plasmodium compositions and methods of use
AU2001274181A1 (en) Composition and method for biocide treatment of surfaces
AU3048501A (en) An improved pharmaceutical composition for treating male erectile dysfunction
EP1161255A4 (fr) Procedes et compositions pour le traitement de la dyserection
HUP0300860A3 (en) Pharmaceutical compositions suitable for treatment of urinary dysfunction
AU2001255696A1 (en) Telomerase inhibitors and methods of their use
AU2002246924A1 (en) Treatment of erectile dysfunction with rho-kinase inhibitors
IL155775A0 (en) Treatment of male sexual dysfunction
AU8906201A (en) Methods and compositions for the treatment and prevention of sexual dysfunction
AU2001281396A1 (en) Novel compositions and methods for treatment of male erectile dysfunction
IL166273A0 (en) Methods of treatment of male erectile dysfunction
AU2002337983A1 (en) Composition and method for treating erectile dysfunction and reducing fibrosis in erectile tissue of the human penis
AU2002210887A1 (en) Methods of and pharmaceutical compositions for improving implantation of embryos
AU2001253560A1 (en) Methods of treatment
AU2001275381A1 (en) Telomerase inhibitors and methods of their use
AUPQ876400A0 (en) Compositions and method of using them